By
Drug Target Review2025-10-03T09:21:07
Researchers have developed a new blood test method, CloneSeq-SV, that tracks treatment-resistant ovarian cancer cells over time. The approach could help predict recurrence and guide targeted therapies.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2023-03-20T13:41:33
Sponsored by Bio-Techne
2023-03-02T13:57:58
Sponsored by Cell Signaling Technology
2023-03-30T09:15:30
Sponsored by Halo Labs
2023-07-03T10:28:23
Sponsored by Merck
2024-02-01T11:52:50
Sponsored by Leica Microsystems
2023-01-05T14:41:33
Sponsored by Cell Signaling Technology
Site powered by Webvision Cloud